Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin - 12/09/19
, Julia Dai, MD c, Shamir Geller, MD a, Melissa Pulitzer, MD d, Andy Ni, PhD e, Patricia L. Myskowski, MD a, Alison Moskowitz, MD f, Jinah Kim, MD g, Eric K. Hong, BS c, Sophia Fong, BS c, Richard T. Hoppe, MD h, Youn H. Kim, MD i, Steven M. Horwitz, MD fAbstract |
Background |
Whole-body imaging is the current standard of care for staging all patients presenting with skin lesions of B-cell lymphomas (BCLs), regardless of skin disease extent; however, supporting data are lacking.
Objective |
To determine the clinical utility of imaging in the detection of systemic involvement in low-grade cutaneous BCLs in the skin.
Methods |
Retrospective cohort analysis of patients presenting with cutaneous lesions of BCLs at Memorial Sloan Kettering Cancer Center and Stanford University during 1997-2016.
Results |
At initial staging, of the 522 patients, extracutaneous disease was noted in 3.6% and 8.8% of patients with marginal zone lymphoma (MZL, n = 306) and follicle center lymphoma (FCL, n = 216) histology, respectively. In patients with systemic involvement, imaging alone identified 81.8% (9/11) of MZL cases and 89.4% of follicular lymphoma cases. In primary cutaneous MZL, 1.7% of patients subsequently had extracutaneous involvement (median follow-up 45 months), and in primary cutaneous FCL. 3.0% subsequently had extracutaneous involvement (median follow-up 47 months).
Limitations |
This was a retrospective study.
Conclusion |
Imaging is effective at identifying patients with systemic involvement in indolent BCLs present in the skin; however, incidence is low. After negative initial staging, primary cutaneous MZL patients may be followed clinically without routine imaging.
Le texte complet de cet article est disponible en PDF.Key words : imaging, primary cutaneous B-cell lymphoma, prognosis, systemic involvement of cutaneous B-cell lymphoma
Abbreviations used : BCL, BM, CBCL, CT, DLBCL, FCL, FL, MSKCC, MZL, pc-FCL, pc-MZL, PET/CT, WHO
Plan
| Drs Dai and Geller contributed equally to this study. |
|
| Senior authors Drs Kim and Horwitz contributed equally to this study. |
|
| Funding sources: Supported in part by the National Institutes of Health, National Cancer Institute Cancer Center Support Grant P30 CA008748. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 81 - N° 4
P. 970-976 - octobre 2019 Retour au numéro
Article précédent
- Prevalence and determinants for xerosis cutis in the middle-aged and elderly population: A cross-sectional study
- Selma Meki?, Leonie C. Jacobs, David A. Gunn, Andrew E. Mayes, M. Arfan Ikram, Luba M. Pardo, Tamar Nijsten
- Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands
- Sanne E. Uitentuis, Marieke W.J. Louwman, Alexander C.J. van Akkooi, Marcel W. Bekkenk
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?